Hospital Acquired Disease Testing Market -Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2027

The Global Hospital Acquired Disease Testing Market is segmented by Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 539 million in 2016 and is projected to exhibit a CAGR of 19.7% over the forecast period (2017-2025), as highlighted in a new report published by Coherent Market Insights.
Hospital acquired diseases are an insidious problem. According to Centers for Disease Control and Prevention (CDC), 2016, about one in 25 hospital patients have at least one have hospital associated infection at any given day. They could be systemic, localized or, can involve any system of the body. Reducing the hospital acquired infection across healthcare sector could help improve patient management.
In 2017, around 11 samples of water were collected from Wide Bay hospital and Health services facilities in U.S., out of which nine samples were found positive with Legionella, which causes lung infection. Remediation measures were taken such as chlorine and heat treatment, pipes and tape replacements, and disposal of water through proper systems. According to BMJ journal, in 2012, healthcare acquired diseases can be prevented.
Medicare and private insurance company is eliminating the reimbursement due to high rate of hospital-acquired infection (HAI) incidence during 2014 and 2015, adding economic pressures on hospitals to reduce hospital acquired diseases.
Hospital acquired infections are usually caused when the shared equipment are not properly cleaned. Philips Healthcare is contributing towards the management of hospital acquired infections, which in turn, increases the cost of hospital acquired diseases testing and even leading to death of patients. The company provides single-patient use devices such as NIV mask, blood pressure cuffs, peripheral capillary oxygen saturation (Sp02) sensors, and ECG leads. These devices are designed to last for an entire patient stay at the hospital, which in turn, support the goal of reducing hospital acquired infections.
Browse 33 Market Data Tables and 30 Figures spread through 140 Pages and in-depth TOC on Hospital Acquired Disease Testing Market by Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025
In 2017, Patrona Medical and Kopis developed a medical device using Zipit's loT platform and also announced their development partnership with Patrona Medical's Foley Garde solution. Aiming for improved care and mediation associated with hospital-acquired infections with an automated interface created by Foley Grade solutions to assist timely detection of catheter, which is the major cause of urinary tract infection and also reduction in cost associated with infection.
A new device, known as Surfaceskins was developed to combat the deadly hospital acquired infections in 2017, which is incorporated with engineered textile design that are used on hospital doors in place of traditional aluminum door plate, aiming to bolster hand hygiene.
Antibiotic resistance is a major factor associated with hospital acquired disease testing. In 2012, Curetis Unyvero System launched molecular device which are used for rapid detection of microorganism and antibiotic resistance gene.
Key takeaways of the market:
• The global hospital acquired disease testing market is expected to exhibit a CAGR of 19.70% over the forecast period (2017-2025), owing to rising geriatric population. Asia Pacific is expected to exhibit a high growth rate, in terms of value in the global hospital acquired disease testing market over the forecast period.
• Among test type, urinary tract infection is expected to hold a major share in the market over the forecast period. This is mainly due to prevalence of nosocomial infections which are caused by UTI, as they have higher antibiotic resistance compared to normal UTIs.
• The global hospital acquired disease testing market is characterized by market expansion in Asia Pacific and Latin America, which is expected to generate higher market revenue, due to increasing incidence of hospital acquired diseases.
Some of the major companies operating in the global hospital acquired disease testing market are Diatherix Laboratories, Life Technologies, Cantel Medical Corporation Meridian Biosciences, Qiagen GmbH, Nordion, Roche, and Cepheid.